There is increasing evidence that nitric oxide (NO) is an important molecular messenger involved in a wide variety of biological processes. Recent data suggest that NO is also involved in the regulation of the cerebral circulation. Thus, NO participants in the maintenance of resting cerebrovascular tone and may play an important role in selected vasodilator responses of the cerebral cir culation. Furthermore, evidence has been presented sug gesting that NO participates in the mechanisms of cere bral ischemic damage. Despite the widespread attention 175 that NO has captured in recent years and the large num ber of studies that have been published on the subject, there is considerable controversy regarding the role of this agent in cerebrovascular regulation and in ischemic damage. In this paper the results of investigations on NO and the cerebral circulation are reviewed and the evi dence for and against a role of NO is critically examined.
Nitric oxide (NO) has recently emerged as a ubiq uitous molecular mediator involved in a wide vari ety of biological processes in several organ systems (Moncada, 1992) . In brain, NO, or a related com pound, appears to be a nonconventional neuro transmitter that may also participate in the regula tion of the cerebral circulation (Gally et aI., 1990; Snyder, 1992) . NO is a diffusible, short-lived, and highly reactive chemical species that is difficult to measure in vivo (Archer, 1993) . Therefore, studies on the role of NO have most often utilized agents that inhibit the activity of NO synthase (NOS), the enzyme that synthesizes NO from L-arginine (Bredt et aI., 1991) . These agents, termed NOS inhibitors, are N"'-substituted L-arginine analogues that inhibit NOS competitively (Palmer et aI., 1988; Sakuma et aI., 1988) .
In this article the effects of NOS inhibitors on the regulation of cerebral circulation and on cerebral ischemic damage are critically reviewed. Despite the ever-increasing number of studies on this sub ject, the role of NO in cerebrovascular regulation and in the pathophysiology of cerebral ischemia is far from clear and a considerable degree of contro versy remains. In the following pages we review the evidence, examine both sides of controversial is sues, and, whenever possible, attempt to reconcile the differences.
NO SYNTHASE AND ITS INHIBITORS
The synthesis of NO and its inhibition by L-argi nine analogues have been discussed in detail in re cent reviews (e.g., Moncada, 1992; Nathan, 1992; Stuehr and Griffith, 1992) and are briefly summa-rized below. NO is synthesized from the semiessen tial amino acid L-arginine by the enzyme NOS (for a review see Stuehr and Griffith, 1992) . At least three isoforms of NOS have been identified: two constitutive isoforms, neuronal and endothelial NOS, and an inducible isoform first isolated in mac rophages (for a review see Nathan, 1992) . The neu ronal and endothelial isoforms are activated by Ca 2 + transients and produce NO phasically (for a review see Moncada, 1992) . The inducible isoform is induced by endotoxins and cytokines, a process that requires DNA transcription and protein synthe sis. Unlike the constitutive isoforms, inducible NOS is not activated by Ca 2 + and, once expressed, produces NO continuously (for a review see Nathan, 1992) . The most widely used NOS inhibitors are nitro L-arginine methyl ester (L-NAME), nitro-L-arginine (L-NA), and N-monomethyl L-arginine (L-NMMA) (Nathan, 1992) (Fig. 1) . These compounds block the conversion of L-arginine to L-citrulline without af fecting the cyclic GMP (cGMP) response induced by NO donors such as nitroprusside, and they in hibit NO production as assessed by both direct and J Cereb Blood Flow Metab. Vol. 14. No. 2. 1994 indirect methods (Moncada, 1992; Archer, 1993) . L-NAME, L-NA, and L-NMMA are chemically modified from L-arginine. L-NA and L-NMMA con tain a N02 and a CH3 substitution at the terminal guanidino nitrogen, respectively, whereas L-NAME contains both a N02 substitution at the terminal nitrogen and an alkyl esterification at the carboxy terminus (Fig. 1) . In most instances, NO synthesis is blocked competitively, although noncompetitive inhibition may occur, depending upon the dosage and treatment duration (Dwyer et aI., 199 1) . In many models, the enzyme inhibition is stereospe cific so that the L-but not the D-enantiomer inhibits the reaction and only L-arginine attenuates the in hibition. However, L-NAME, L-NA, and L-NMMA inhibit both the constitutively expressed and the in ducible enzymes and do not discriminate between constitutive isoforms with great specificity. L-NMMA is less potent than L-NA in inhibiting the constitutive enzyme. Recent studies emphasize the importance of con firming inhibition of enzyme activity after adminis tering L-arginine analogues (Irikura et aI., 1993 (Irikura et aI., , 1994 . In vascular preparations, NOS inhibition has been assessed by measuring vessel caliber or ten sion changes in response to topical acetylcholine (ACh) or other compounds that promote NO pro duction in the endothelium. In complex systems such as brain, the isotopic conversion assay devel oped by Bredt and Snyder (1989) provides a reason able index of enzyme inhibition. The significance of assessing enzyme activity is illustrated by one study in which r(CBF) response was measured during whisker stimulation following topical L-NAME or L-NA under a closed cranial window (Irikura et aI., 1993 (Irikura et aI., , 1994 . The CBF response was minimally de creased by L-NAME or L-NA (1 mM) at 30 min after application, despite blockade of pial vessel di lation to topical ACh or to intravenous infusion of L-arginine. At 60 min after application, the attenu ation of the regional CBF response was significant and was linearly correlated with the extent of en zyme inhibition in cortex beneath the window, as assessed by the isotopic conversion assay. In pre liminary studies, the rCBF response to CO2 inhala tion exhibited a similar relationship to cortical NOS activity (Irikura and Moskowitz, unpublished ob servations) . Had these experiments been termi nated after only 30 min, incorrect conclusions would have been reached.
Concerns have been raised regarding the speci ficity of the NOS inhibitors. These concerns appear justified in view of the demonstration that (a) L-NAME and other L-arginine analogues containing alkyl ester substitutions at the carboxy terminus are muscanmc antagonists (Buxton et al., 1993) ; (b) L-NAME and L-NMMA have inhibitory effects on cytochrome c reduction by ferrous iron and, possi bly, effects on other iron-containing reactions (Peterson et al., 1992) ; (c) L-NMMA blocks vasodi lation caused by amiloride and dibutyrl cyclic AMP (cAMP), which are not endothelium dependent (Thomas and Ramwell, 1992) ; (d) L-NMMA, like other cationic amino acids, competes with L-argi nine for uptake by a saturable transport system within the endothelium, a feature not shared by L-NA or L-NAME (Bogle et al., 1992) ; (e) L-NMMA, but not L-NA, can be metabolized by endothelial cells to L-citrulline, which in turn serves as a precursor for NO synthesis by conversion to L-arginine (Hecker et al., 1990) ; and (t) L-NMMA induces NO synthesis in isolated arterial segments (Archer and Hampl, 1992) . While it is important to recognize that NW-substituted arginine analogues have pharmacological actions not related to NOS inhibition, it must also be stressed that most of these effects are not stereospecific and, as such, can be avoided by testing both the L-and the D-en antiomers.
Taken together, the available evidence (a) favors the use of L-NA or L-NAME as an inhibitor of NOS activity within the cerebral circulation, (b) empha-sizes the importance of enantiomeric specificity studies, and (c) demonstrates the significance of as sessing inhibition of activity or NO production when using L-arginine analogues.
RESTINGCBF
Several investigators employed NOS inhibitors to determine whether NO, or a related compound, is responsible for the maintenance of resting vascular tone in vivo. Faraci (1990) found that topical appli cation of L-NMMA constricts the rat basilar artery, an effect reversed by L-but not D-arginine. Rosen blum et al. (1990) in mouse and Busija et al. (1990) in piglet observed that L-arginine dilates pial arteri oles in a dose-dependent manner. Tanaka et al. (199 1) demonstrated that systemic administration of L-NMMA (30 mg/kg) reduces the resting CBF by 20-30% in awake rats. These findings were con firmed in different species with intravenous admin istration or topical application of NOS inhibitors. All the papers cited in Tables 1-3, with few excep tions (ladecola, 1992a; Iwamoto et al., 1992a; Buchanan and Phillis, 1993) , found that NOS inhib itors reduce the resting CBF. Because NOS inhib itors do not affect resting cerebral glucose utiliza tion (Iadecola and Xu, 1994; Wang et al., 1993a) or Sokoloff et al. (1992) Rat/awake L-NAME, 30 mg/kg, i.v.
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Subscripts: iap, iodoantipyrine ; ldI, laser Doppler tlowmetry; mic , microspheres; vout, venous outflow; xe, xenon clearance ; i.c.v. , intracerebroven tricularly ; i.v., intravenously; t.a., topical application. Attenuation is expressed as percentage reduction of the increase in CBF observed in the absence of NOS inhibitors. Increases in CBF in the presence of NOS inhibitors were calculated as percentage of resting CBF in the presence of the inhibitor. a L-NAME reduced cerebrovascular reactivity to changes in Peo2 (�CBF/Peo2) but did not affect the reduction in calculated cerebrovascular resistance elicited by hypercapnia. cerebral oxygen consumption (e.g., Kozniewska et al., 1992; McPherson et al., 1994; Wang et al., 1993a; Wilson et al., 1993) , their effect on resting CBF cannot be attributed to a depression in cere bral energy metabolism. These observations strongly suggest that NO participates in the main tenance of the "normal" tone of the brain's arterial system. Since systemic NOS inhibition increases total peripheral vascular resistance, it seems that a basal level of NO is required to keep resistance ves sels, in brain as well as in the periphery, in a some what relaxed state. The NO contribution to resting vasodilator tone, however, varies among species and brain regions. For example, in the cat cerebral cortex NO does not contribute substantially to maintain the resting CBF or pial arterial diameter (Kovach et al., 1992; Wei et al., 1992) .
The source(s) of the NO responsible for mainte nance of the resting CBF remain to be elucidated. In brain, the constitutive isoform of NOS is present in neurons, astrocytes, perivascular nerves, and ce rebral endothelial cells (Bredt et al., 1990; Murphy et al., 1993) (Fig. 2) .
Neurons and astrocytes. NOS-containing neu- intravenously; t.a., topical application. Attenuation is expressed as percentage reduction of the increase in CBF observed in the absence of NOS inhibitors. Increases in CBF in the presence of NOS inhibitors were calculated as percentage of resting CBF in the presence of inhibitor.
FIG. 2 Illustration of the cellular localization of NOS at the microvascular level in the cerebral circulation. Inducible (iNOS) and constitutive (cNOS) isoforms of NOS have been described in cerebral endothelial cells and astrocytes. In smooth muscle cells, only iNOS has been de scribed thus far. cNOS is also present in a re stricted population of neurons, some of which have propesses in close association with cere bral microvessels, and in perivascular nerves originating from selected cranial autonomic ganglia. The "extrinsic" perivascular nerves innervate cerebral arterioles up to a diameter of 50-100 11m and, unlike the "intrinsic" pro cesses originating from NOS neurons, do not reach intraparenchymal microvessels, i.e., vessels located beyond the Virchow-Robin space (see text for references).
rons have a large number of processes that make close contact with intracerebral blood vessels (Ia decola et aI., 1993a; Regidor et aI., 1993) . There fore, NO produced in these processes during cal cium transients could influence the resting vascular tone. In dog neurohypophysis, NOS inhibitors re duced CBF by 87%, a decrease comparable to that obtained by blocking neuronal depolarization with tetrodotoxin (TTX) (Wilson et aI., 1993) . Therefore, it has been proposed that neuronal NO is mainly responsible for maintaining the resting CBF in neu rohypophysis (see also Kovach et aI., 1993) . How ever, in other brain regions the effects of NOS in hibition are less marked (Tanaka et aI., 199 1; Ko vach et aI., 1992) , suggesting that the contribution of neuronal NO to the maintenance of resting CBF may be regionally specific. Regional variations in blood-brain barrier permeability may also contrib ute to the regional pattern of CBF reductions elic ited by systemic administration of NOS inhibitors. Except for the neurohypophysis, there is no close correlation between the regional density of NOS neurons, or NOS activity, and regional cerebrovas cular effects of NOS inhibition (Bredt et aI., 1990; Forstermann et aI., 1990; Tanaka et aI., 199 1; Ko vach et aI., 1992; Wilson et aI., 1993) . Regarding other neural sources of NO, it is unlikely that NO generated in perivascular nerves is responsible for the resting vasodilator tone because ablation of the major source of these nerves, the sphenopalatine ganglia, does not affect the resting CBF (Seylaz et al., 1989) . However, these nerves may originate from multiple sources (Nozaki et aI., 1993; Suzuki et aI. , 1993) and total denervation is difficult to
achieve. Although constitutive NOS activity has been reported in astrocytes (for a review see Mur phy et aI., 1993), whether these cells contribute to the maintenance of resting CBF remains to be es tablished.
Endothelium. Another important source of NO is the endothelium. NOS inhibitors reduce the vascu lar diameter in isolated large cerebral arteries and decrease their cGMP content (Alafaci et aI., 1993; Cosentino et aI., 1993; Tian et aI., unpublished obser vations; Wang et aI., 1993b) . Considering that no constitutive NOS activity has been reported in vas cular smooth muscles (for review see Moncada, 1992) , the findings suggest that endothelial NO may be responsible for the resting vasodilator tone of large vessels. Perhaps shear forces associated with flowing blood may provide a stimulus for NO syn thesis in cerebral arteries (Gaw and Bevan, 1993) . In vivo NOS inhibitors constrict small pial arteries, an effect that is abolished by selective lesioning of the endothelium by the laser-dye technique (Rosen blum et aI., 1990) . This observation supports the hypothesis that endothelial NO is important for the vasodilator tone of pial vessels. On the other hand, lesioning of endothelial cells by the laser-dye tech nique does not reduce the resting vascular diameter of small pial arteries . This finding argues against an endothelial source of NO in small pial vessels and supports the hypothesis that the role of endothelium-derived NO may differ in large arteries and small pial vessels (Faraci, 1991) . Alternatively, after endothelial damage other sources of NO may compensate for the loss of endothelial NO so that the resting vascular tone does not increase.
It appears from this discussion that NO partici pates in the maintenance of the resting CBF but the source(s) of NO remains to be elucidated. Although the evidence suggests that both endothelial and neu ronal NO may participate, their relative contribu tion differs depending on the animal species, the brain region, and, in the case of endothelial NO, the segment of the cerebral vasculature.
CEREBROVASCULAR AUTOREGULATION
AND VASOMOTION
Autoregulation. The term cerebrovascular auto regulation refers to the property of cerebral resis tance vessels to dilate when arterial pressure (AP) is lowered and to constrict when AP is increased (Las sen, 1964; Heistad and Kontos, 1983; Paulson et aI., 1990) . The purpose of this mechanism is to maintain constant flow during variations in cerebral perfu sion pressure. This mechanism is operational within a certain range of AP, beyond which CBF will fol low AP passively (upper and lower limits of auto regulation). The observation that the vascular ad justments responsible for autoregulation depend on the integrity of the endothelium (Gotoh et aI., 1987; Harder, 1987; Katusic et aI., 1987) prompted the investigation of whether endothelial NO could be the vasodilating agent responsible for the changes in vascular diameter. However, Wang et aI. (1992a) found that, although L-NA reduces the resting CBF, the lower limit of autoregulation is not affected. This observation suggests that the cerebrovascular vasodilation associated with hypotension is not me diated by NO. Similar conclusions were reached by other investigators (DeWitt et aI., 1992; Buchanan and Phillis, 1993) . Tanaka et ai. (1993) recently re ported that NOS inhibitors impair cerebrovascular autoregulation during moderate hypotension in rat (AP reduction from 144 to 102 mm Hg). However, in this study there was no control group in which the effects of hypotension on CBF were examined in the absence of NOS inhibition. Therefore it could not be established whether autoregulation was pre served in the experimental preparation used. We are not aware of studies on the effects of NOS in hibition on the upper limits of cerebrovascular au toregulation.
Vasomotion. The diameter of cerebral arteries and arterioles exhibits spontaneous periodic oscil lations resulting in cyclic variations in CBF at a frequency of 0.5-12/min (for references see Hudetz et aI., 1992) . This phenomenon, commonly referred to as vasomotion, is present also in the systemic circulation (Kastrup et aI., 1989; Gustafsson et aI., 1993) and is induced by several stimuli including J Cereb Blood Flow Metab, Vol. 14, No. 2, 1994 vasoconstrictors and hypotension (Fujii et aI., 1990; Hudetz et aI., 1992; Kim et aI., 1993) . Dirnagl et ai. (1993b) have presented evidence that in the cerebral circulation L-NA enhances vasomotion, while Kim et ai. (1993) have shown that NO attenuates vaso motion in isolated intraparenchymal arterioles. This is in contrast to the mesenteric circulation, wherein NO has been proposed to play a permissive role in vasomotion (Gustafsson et aI., 1993) . As for the ce rebral circulation, the data suggest that NO is not necessary for vasomotion and support the hypoth esis that this phenomenon, like autoregulation, is purely myogenic in nature. Enhanced vasomotion by NOS inhibitors could very well be a nonspecific consequence of the vasoconstriction associated with inhibition of NO synthesis.
HYPERCAPNIA
A number of studies have used NOS inhibitors to investigate the role of NO in the cerebrovasodila tion elicited by hypercapnia (Table 1 ). The majority of these studies has found that NOS inhibitors at tenuate the increases in CBF elicited by hypercap nia in rat, cat, dog, and rabbit. The effect is dose dependent, stereospecific, and reversed by coad ministration of L-arginine (Iadecola, 1992a; Wang et aI., 1992b; Dirnagl et aI., 1993a; Iadecola et aI., 1993b) . The magnitude of the reduction of the re sponse ranges from 36 to 94% (expressed as per centage reduction of the flow increase in untreated animals), depending on the dose and route of ad ministration of the inhibitor. With the exception of the study by Fabricius and Lauritzen (1994) , in the rat cerebral cortex the greatest reductions have been observed with topical application (Table 1) . The attenuation cannot result from a nonspecific reduction in vascular reactivity because the vasodi lation elicited by papaverine, nitroprusside , hy potension, moderate hypoxia, or activation of the reticular formation is not aff ected or is enhanced by L-NA, at concentrations that inhibit the CO2 re sponse (Iadecola, 1992a,b; Wang et aI., 1992a; Ia decola and Xu, 1994; Irikura et aI., 1994; Niwa et aI., 1993; Pelligrino et aI., 1993a) .
On the other hand, three studies have found that NOS inhibitors do not attenuate the hypercapnic cerebrovasodilation (Table 1) . Adachi et aI. (1992) found that L-NAME does not attenuate the in creases in CBF elicited by inhalation of 10% CO2, Amano et ai. (1993) reported that in cat L-NMMA does not affect the magnitude of increases in CBF eHcited by a 11.9 mm Hg elevation in Pco2• Goadsby and Hoskin (1993) , also in cat, found that intravenous L-NAME does not attenuate the CO2 response. The reasons for this discrepancy are un clear at present. However, there are important dif ferences in the experimental protocols of these studies that may help explain the apparent conflict. First, in the study by Adachi et ai. (1992) , hyper capnia was induced by administration of 10% CO2, Although Peo2 was not measured, it is likely that the degree of hypercapnia was greater than that used in studies in which NOS inhibitors were found to be effective (Table 1) . This issue is important because the attenuation of hypercapnic vasodilation by NOS inhibitors is maximal at a Peo2 of 50-60 mm Hg and does not occur at a Peo2 > 100 mm Hg (Ia decola and . Therefore, it is likely that in the study by Adachi et ai. (1992) the level of hypercapnia was beyond the range in which NOS inhibitors are effective. Second, in the study by Amano et ai. (1993) L-NMMA, a NOS inhibitor less potent than L-NA or L-NAME (Moncada, 1992) , was topically applied for 5 min and then infused into the carotid artery for 5 additional min before the induction of hypercapnia. In studies in which atten uation was found, a longer interval between admin istration of NOS inhibitors and hypercapnia chal lenge was used. It is therefore conceivable that in the study by Amano et ai. (1993) the duration of administration was not sufficient to inhibit NOS in brain adequately. In support of this hypothesis are the findings that in rat (a) the effects of NOS inhib itors on the hypercapnic vasodilation are time de pendent and are well developed 30--45 min after in travenous administration or topical application of the agents (Fabricius and Lauritzen, 1994; Iadecola and Zhang, 1994 ; Irikura and Moskowitz, unpub lished observations); (b) the inhibition of brain NOS activity after administration of NOS inhibitors is also time dependent, being greatest 2 h after intra venous administration and 60 min after topical ap plication (Irikura et aI., 1993 (Irikura et aI., , 1994 Xu et aI., 1993) ; and (c) the degree of NOS inhibition correlates with the degree of attenuation of the hypercapnic re sponse (Irikura and Moskowitz, unpublished obser vations). Another explanation for the discrepant preliminary findings of Amano et ai. (1993) , as well as those of Goadsby and Hoskin (1993) , is that in cat NO does not participate in the hypercapnic cerebrovasodilation. However, this possibility is unlikely because Sandor et al. (1994) observed that L-NAME (30 mg/kg, i.v.) attenuates the CO2 re sponse substantially also in cat.
Therefore, the majority of the data supports the hypothesis that NO participates in the cerebrova sodilation elicited by hypercapnia. However, the precise role of NO in the response is not entirely clear. It is widely accepted that the hypercapnic vasodilation is mediated by a decrease in perivas cular pH induced by the increase in tissue Peo2 (Lassen, 1968; Heistad and Kontos, 1983) . Data from isolated rat cerebral arteries suggest that ex tracellular acidosis is mainly responsible for the re laxation of vascular smooth muscles in hypercapnia (Tian et aI., unpublished observations). Therefore, NO could participate in the mechanisms by which extracellular acidosis induces smooth muscle relax ation. This hypothesis is supported by the finding that NOS inhibitors attenuate the vasodilation elic ited by topical application of acidic cerebrospinal fluid (Niwa et aI., 1993) . Furthermore, NOS inhib itors attenuate the relaxation elicited by selective extracellular acidosis also in isolated cerebral arter ies (Tian et aI., unpublished observations). How ever, the mechanisms of such an effect remain un clear at present.
It is unlikely that NO is the only vasoactive agent involved in the CBF response to hypercapnia, be cause (a) NOS inhibitors attenuate the vasodilation only within a certain range of Peo2 levels, and (b) even in the most susceptible Peo2 range, a residual response is always present after NOS inhibition. Therefore, other factors are likely to participate in the vasodilation, particularly at a Peo2 > 100 mm Hg. Indeed, the marked reduction of the hypercap nic response by indomethacin supports the involve ment of other mechanisms (e.g., Wang et aI., 1993c) . Wang et ai. (1993b) reported that in the iso lated rat basilar artery, as in the rat aorta (Fukuda et aI., 1990) , hypercapnia does not increase cGMP. Since NO produces vasodilation by activating sol uble guanylyl cyclase and increasing cGMP in vas cular smooth muscles (Moncada, 1992) , the findings suggest that NO is not the final mediator of the vasodilation elicited by hypercapnia. However, these preliminary observations need to be con firmed and extended, particularly in view of the fact that small and/or transient increases in vascular cGMP could be easily missed.
The source(s) of NO in hypercapnia has not yet been determined and the evidence currently avail able does not favor any particular cell type. The following observations argue against the source of NO being in neurons or perivascular nerves: (a) In vitro, the vasodilator response to CO2 is preserved in isolated cerebral arteries (Wang et aI., 1993b); in vivo the CO2 response is not affected by lesions of the sphenopalatine ganglia resulting in depletion of NOS-containing perivascular nerves (Iadecola et aI., 1993b) ; (c) NOS inhibitors attenuate the vascu lar relaxation induced by hypercapnia also in iso lated rat cerebral arteries (Tian et aI., unpublished observations; Wang et al., 1993b) ; and (d) the va-sodilator response is preserved in brain regions wherein local neurons have been destroyed using the excitotoxin ibotenic acid or in which neural activity is blocked by TTX or Mg 2 + (ladecola et aI., 1987; Fabricius and Lauritzen, 1994; Iadecola and Ebner, 1993) . Whether astrocytic NO participates in the hypercapnic vasodilation remains to be established. On the other hand, NO synthesis in hypercapnia could take place within the vascular wall. It is, how ever, 'unlikely that the source of NO is in smooth muscle cells because no constitutive NOS activity has been reported in these cells (for review see Moncada, 1992) . Regarding endothelial cells, the observation that the CO2 response in isolated cere bral vessels is not affected by removal of the endo thelium suggests that, at least in large vessels, the source of NO is not in endothelial cells (Toda et aI., 1993) . However, at the high Peo2 used in that study (> 100 mm Hg) the vasodilation is not dependent on NO, and nonendothelial factors may mediate the response. Gotoh et aL (1987) in cat pial arteries found that endothelial damage with ultraviolet light does not attenuate the CO2 response. Similarly, the hypercapnic dilatation of rat pial vessels is not in fluenced by lesioning of endothelial cells using the light-dye technique (Wang et aI., 1993d) . One po tential problem with assessing the effects of seg mental endothelial lesions is that the vasodilator re sponse to CO2 could be, in part, propagated from vessels upstream or downstream (Heistad and Kon tos, 1983) . The vasodilation to CO2 may therefore not be affected by focal endothelial lesions because a large component of the vascular response may originate from sites remote from the lesion. Another observation that argues against an endothelial source of NO is that the pial vessel dilatation elic ited by topical ACh, a response mediated by endo thelial NO, is abolished after a few minutes of top ical application of NOS inhibitors, whereas the va sodilation elicited by hypercapnia requires prolonged application times (45-60 min) (Faraci, 199 1; Iadecola, 1992a; Irikura and Moskowitz, un published observations ; Wei et aI., 1992; Dirnagl et aI., 1993a; Fabricius and Lauritzen, 1994) . There fore, the cellular site of NO production in hyper capnia remains to be determined.
To summarize, there is substantial evidence that NOS inhibitors attenuate the increase in CBF elic ited by hypercapnia, although NO may not be the final mediator acting on vascular smooth muscle cells to produce vasodilation. Thus, NO synthesis is a necessary step for the hypercapnic vasodilation to occur. However, NO is not the only factor involved in the response and other vasodilator agents are likely to participate. 
HYPOXIA
Several studies have examined the role of NO in the cerebrovasodilation elicited by hypoxia in dif ferent species (Table 3) . Kozniewska et aL (1992) reported that, in rat, systemic administration of L-NMMA does not significantly attenuate the in creases in CBF elicited by hypoxia (P a02' 33 mm Hg). Similarly, Pelligrino et aL (1993a) and Bucha nan and Phillis (1993) reported no attenuation of the CBF response to hypoxia by the systemic adminis tration of L-NAME. In addition, Ichord et aL (1994) in piglet and McPherson et aL (1994) in dog reported that L-NAME, while inhibiting brain NOS catalytic activity by 90%, does not attenuate the hypoxic cerebrovasodilation. On the other hand, Iwamoto et aL (1992a) reported that, in awake sheep, L-NA at tenuates the increase in CBF elicited by hypoxia (P a02 ' 37-38 mm Hg) by 63%. Pelligrino et aL (1993b) examined the effect of topical application of L-NAME on the pial arteriolar dilatation accompanying moderate or severe hypox ia. In control rats, moderate hypoxia (Pao2, 45 mm Hg) increased arteriolar diameters by -20%, whereas severe hypoxia (Pao2, 33 mm Hg) was ac companied by a further increase to 35-40% over baseline. Following 45-60 min of topical L-NAME suffusion, moderate hypoxia still produced a 20% increase in diameter, but no further increases were seen upon exposure to severe hypoxia. On the other hand, in anesthetized rats subjected to graded hyp oxia, Berger et aL (1993) observed that L-NAME attenuates the vasodilation in moderate and severe hypoxia as well. These observations are still pre liminary and need to be confirmed and extended.
Methylene blue (MB), an inhibitor of soluble gua nylyl cyclase, the enzyme that mediates most of the actions of NO (for a review see Moncada, 1992) , has also been used to study the role of NO in hyp oxic cerebrovasodilation, with variable results (Ta ble 2). These findings must be interpreted with cau tion because of the lack of specificity of MB as a guanylyl cyclase inhibitor, particularly when ad ministered systemically.
Although the observations that hypoxia increases cGMP in isolated cerebral vessels and that this ef fect depends, in part, on the integrity of the endo thelium suggest that endothelium-derived NO par ticipates in the vasodilator response (Pearce et aI., 1990 ), this hypothesis is not supported in full by the in vivo studies mentioned above. These findings, collectively, may indicate that the contribution of NO to the hypoxic cerebrovasodilation is small and that other vasodilator agents may play a more prominent role. In moderate hypoxia, adenosine may be the principal mediator, at least in the rat (Morii et aI., 1987) .
FUNCTIONAL ACTIVATION
One of the major factors regulating CBF is neu ronal activity (for a review see Edvinsson et aI., 1993; Iadecola, 1993) . Several studies have investi gated the role of NO in the vascular responses elic ited by neural activation using different models (Ta ble 3). Focal activation of the cerebral cortex has been produced by stimulation of the sciatic nerve, by vibrissal stimulation, or by topical application of excitatory amino acids. Global brain activation was elicited by stimulation of the brain-stem reticular formation. The results of these studies are discor dant. Some laboratories found that NOS inhibitors attenuate the increases in CBF elicited by neural activation, while others found that these agents have no effect. Different results were obtained even by laboratories that used identical activation para digms. Although the reasons for these conflicting findings are unclear at present, some comments are in order.
Regarding the cerebrovascular effects of vibrissal stimulation, in the two studies in anesthetized rats NOS inhibitors were topically applied and this treatment attenuated the CBF response (Dimagl et aI., 1993a; Irikura et aI., 1994) . In contrast, in stud ies in awake rats, in which agents were adminis tered intravenously, either no effect was found (Wang et aI., 1993a) or a nonsignificant attenuation was observed [22% reduction (Adachi et aI., 1993)].
Although the presence or absence of anesthesia may also play a role, one possible explanation for the difference in the findings of these studies relates to the degree of NOS inhibition. In rat, topical ap plication of L-NA or L-NAME (1 mM) for 60 min inhibits NOS activity by 90% (Irikura et aI., 1994) , whereas a single i. v. administration of L-NAME in hibits brain NOS by -50%, even at the highest doses (Dwyer et aI., 1991; Xu et aI., 1993) . There fore, in rat models, topical application of NOS in hibitors leads to greater NOS inhibition in brain than intravenous administration. This is in contrast to the cat, dog, and piglet, in which a single intra venous injection of L-NAME attenuates brain NOS activity by 70-90% (Ichord et aI., 1994; R. Trayst man, personal communication) . In support of the hypothesis that the attenuation of the CBF response to vibrissal stimulation is related to the degree of NOS inhibition is the finding by Irikura et aI. (1993 Irikura et aI. ( , 1994 ) that attenuation of the CBF response occurs only when NOS inhibition is >50%. In apparent contrast with this hypothesis, however, are the ob-servations that the CBF response to vibrissal stim ulation (a) is attenuated even after intravenous ad ministration of L-NA (Dimagl et aI., 1993a) and (b) is not affected after administration of L-NAME di rectly into the brain ' s ventricular system (Adachi et al., 1993) . Further studies, in which NOS inhibition is documented in each model by measuring brain NOS activity ex vivo, may help reconcile the ap parent contradictions among these results.
Differences in the route of administration of NOS inhibitors and in the degree of NOS inhibition could also explain the discrepancies in the results of stud ies in which activation of the somatosensory cortex was elicited by electrical stimulation of the sciatic nerve ( Table 3 ). In the study by Northington et al. (1992) , L-NA (1 mM) was delivered directly into the tissue via a dialysis fiber and the CBF response to sciatic nerve stimulation was virtually abolished (Northington et aI., 1992) . In contrast, in the study by Ngai et aI. (1993) , L-NA was topically super fused for 10 min and this treatment did not attenuate the increase in pial vessel diameter elicited by sci atic nerve stimulation. In contrast, the vasodilation elicited by topical ACh or hypercapnia was attenu ated. Although NOS activity was not measured, this finding suggests that the degree of NOS inhibi tion required to attenuate the vasodilation elicited by somatosensory activation is greater than that re quired to attenuate the response to hypercapnia or topical ACh.
That NO could participate in the increases in CBF elicited by neural activity is also suggested by the study by Faraci and Breese (1993) . These au thors found that superfusion with L-NA attenuates the increases in CBF elicited by topical application of the excitatory amino acid N-methyl-D-aspartate (NMDA). Because NMDA did not dilate isolated cerebral vessels (Faraci and Breese, 1993) , the find ings suggest a neural source of NO. On the other hand, the increase in CBF elicited by electrical stimulation of the reticular formation, a response probably secondary to global metabolic activation, is not affected by topical L-NA or systemic admin istration of L-NAME (Iadecola, 1992b; Iadecola et aI., 1993b) . These studies suggest that the partici pation of NO in the vasodilation elicited by neural activity may be restricted to certain activation par adigms. These observations, however, need to be confirmed by other laboratories.
To summarize, whether NO is involved in the increases in CBF elicited by neuronal activation re mains controversial. Although some of the discrep ancy in the results may be related to differences in the degree of NOS inhibition in the different stud ies, NO is unlikely to be the universal mediator of "metabolic vasodilation" in brain, as originally pro posed (Gally et aI., 1990) . Thus, NO could be in volved in the vascular response elicited by some, but not all, stimuli resulting in neuronal activation. However, even with activation paradigms in which NOS inhibitors are effective, the flow response is usually attenuated but not abolished, indicating that other vasoactive substances also participate in the vasodilation elicited by neural activity.
NEUROGENIC CONTROL
There is increasing evidence that the cerebral cir culation is influenced by neural pathways "extrin sic" and "intrinsic" to the central nervous system (CNS) (for a review see Edvinsson et aI., 1993) . Neural pathways extrinsic to the CNS originate from cranial autonomic ganglia, give rise to a peri vascular plexus, and innervate cerebral arteries and veins up to vessels 50-100 "",m in diameter. Intrinsic pathways originate from neurons located within the CNS and their activation can modify CBP substan tially. Several studies indicate that NO is involved in the so-called neurogenic regulation of the cere bral circulation.
Extrinsic perivascular nerves. Several investiga tors have presented evidence that the dilatation of isolated cerebral arteries elicited by transmural electrical stimulation is attenuated by NOS inhibi tors or by hemoglobin, a hemoprotein that captures extracellular NO (Toda and Okamura, 1990 ; Gonza les and Estrada, 199 1; Lee and Sarwinsky, 199 1). Because the vasodilation persisted after removal of the endothelium but was abolished by TTX, it was concluded that perivascular nerves are the source of NO. This hypothesis is supported by the finding that stimulation of isolated cerebral vessels de nuded of endothelium increases cGMP in these ves sels, an effect that is also attenuated by TTX and NOS inhibitors (Toda and Okamura, 199 1). Perivas cular nerves containing NOS in the adventitia media border of cerebral arteries were demon strated morphologically using an antibody directed against neuronal NOS (Bredt et aI., 1990) . Subse quent studies found that NOS-containing perivas cular nerves originate from the sphenopalatine gan glia, with some contribution also from the otic and internal carotid ganglia, and innervate the cerebral vasculature (N ozaki et aI., 1993; Iadecola et aI., 1993a; Suzuki et al., 1993) . Electrical stimulation of the sphenopalatine ganglion elicits increases in neo cortical CBP that are attenuated by NOS inhibition, an effect that is reversed, in part, by the adminis tration of L-arginine (Morita-Tsuzuki et aI., 1993). These findings, collectively, strongly suggest that J Cereb Blood Flow Metab, Vol. 14, No. 2, 1994 activation of NOS-containing perivascular nerves release NO, which then acts on the vascular smooth muscles to increase cGMP and produce vasodila tion.
Central pathways. Several studies have indicated that NO participates in the increases in CBP elicited by activation of central pathways. Activation of pathways originating within the rat basal forebrain increases CBP in the cerebral cortex, a response that involves cholinergic pathways and release of ACh in the neocortex (Kurosawa et aI., 1989; Dau phin et aI., 199 1) . Because in many vascular dis tricts ACh produces vasodilation by releasing NO from the endothelium, Raszkiewicz et al. (1992) and Adachi et ai. (1992) studied whether the vasodilator response was mediated by NO. They found that the increases in CBP elicited by stimulation of the basal forebrain were attenuated substantially by NOS in hibitors, suggesting that NO is involved in the va sodilation.
NO has also been implicated in the cholinergic cerebrovasodilation elicited by stimulation of the cerebellar fastigial nucleus (PN). PN stimulation in creases CBP globally and, in neocortex, indepen dently of cerebral glucose utilization (Nakai et aI., 1983) . Topical application or intravenous adminis tration of NOS inhibitors attenuates the response in a dose-dependent and stereospecific fashion (Iade cola, 1992b; Iadecola et aI., 1993b) . The CBP re sponse to PN stimulation is not attenuated by le sions of the sphenopalatine ganglia resulting in de pletion of NOS-containing perivascular nerve fibers (lade cola et aI., 1993b).
These findings indicate that there are central pathways that exert a profound influence on the cerebral circulation by producing NO. However, as discussed in detail elsewhere (Iadecola, 1993) , the precise role of ACh and NO in these vascular re sponses remains to be established, although the data suggest that NO may be the final mediator of vasodilation.
OTHER VASODILATOR RESPONSES OP THE
CEREBRAL CIRCULATION
Hypoglycemia. Studies employing NOS inhibi tors to investigate the role of NO in the cerebrova sodilation elicited by hypoglycemia are quite lim ited and preliminary. In the pentobarbital anesthetized piglet, L-NAME (40 mg/kg, Lv.) attenuates the regional CBP increases accompany ing hypoglycemia only in the cortex and cerebellum (!chord et aI., 1994) . In the rat, Raty and Bryan (1993) showed that L-NAME (30 mg/kg, Lv.) re duces the cortical hyperemic response to hypogly-cemia by 50%. These early results indicate the pres ence of a NO-dependent component, perhaps re gionally selective, in the CBF increases associated with hypoglycemia.
Volatile anesthetics . The increase in CBF asso ciated with 1.4-1.5% isoflurane in pigs (Moore et aI., 1993) and dogs (McPherson et aI., 1993) is mark edly attenuated by L-NAME (40 mg/kg, i.v.). In rats, pial arteriolar dilatation induced by 1-3% halo thane or isoflurane is blocked by topical application of NOS inhibitors (Koenig et aI., 1993a,b) . There fore, NO may play an important role in the vasodi lation elicited by volatile anesthetics. However, the source(s) of NO remains to be established (for a discussion see McPherson et aI., 1993) .
Cortical spreading depression (CSD). A number of reports to date have shown that the vascular re sponse elicited by CSD is quite sensitive to NOS inhibition. The CBF increase and the pial arteriolar dilatation associated with CSD are inhibited in anesthetized cats and rabbit by systemic adminis tration (10 mg/kg, i. v.) or topical application (0. 1 mM) of L-NAME or L-NA (Goadsby et aI., 1992; Deal et aI., 1993; Wahl et aI., 1993) . In awake rats, Duckrow (1993) reported a statistically insignifi cant, 36% reduction in the peak CBF response with L-NAME (30 mg/kg, i.v.), although L-NAME in duced a transient hypoperfusion preceding the hy peremic phase. On the other hand, Fabricius and Lauritzen (1994) found that L-NA, administered in travenously or applied topically , enhances the hy peremic phase of the response in anesthetized rat. Thus, NO synthesis may be an important factor in CSD-induced cerebral hyperemia in some but not all species.
Hemodilution. The possibility that NO synthesis may participate in the CBF increase resulting from hemodilution has received little attention in the lit erature. DeWitt et ai. (1993) reported that intrave nous L-NAME does not attenuate the increases in CBF accompanying blood volume replacement with saline. These preliminary findings suggest that the hyperemic response to hemodilution is independent of NO synthesis.
Seizures. Studies to date on NO-related actions during seizure have employed agents that either in crease excitatory neurotransmission (e.g., bicucul line, pentylenetetrazol) or act directly on excitatory amino acid receptors (e.g., kainate). It is important to assess the effect of NOS inhibition on the elec trical characteristics of the seizures because NO may modulate seizure activity (e.g., Mollace et aI., 1991) . In rat, NOS inhibitors attenuate the increase in hippocampal blood flow elicited by kainate induced seizures (Rigaud et aI., 1993) . In rabbit, topical application of L-NA attenuates the pial va sodilation associated with pentylenetetrazol induced seizures, an effect that is most marked sev eral minutes after the onset of the seizure (Faraci et al., 1994) . In bicuculline-induced seizures NOS in hibition has been reported either to attenuate the hyperemia in rat (Beckman et aI., 1993) or to have no effect in rat (Q. Wang, O. B. Paulson, D. A. Pelligrino, and N. A. Lassen, unpublished observa tions) or cat (Goadsby and Hoskin, 1993) . Thus, at this stage, it is unclear whether NO participates in the cerebral hyperemia associated with seizure. Part of the controversy may be due to differences in experimental models, the protocol of administration of NOS inhibitors, the timing of the CBF measure ment relative to seizure induction, and effects of NOS inhibitors on the intensity of the seizures.
DOES NO PLAY A ROLE IN
CEREBROVASCULAR REGULATION?
The evidence presented above suggests that NO is involved in the maintenance of resting CBF and that it participates in selected vasodilator responses of the cerebral circulation. However, the precise role that this agent plays remains to be defined. NO is clearly not the only mediator of vasodilation in the cerebral circulation because (a) there are va sodilator responses, such as autoregulation, arousal-induced cerebrovasodilation, and, perhaps, hypoxia , in which the participation of NO is not substantial and (b) even in responses in which NO appears to be involved, this agent cannot account in full for the vasodilation, suggesting that other me diators also participate. However, in some re sponses, such as functional activation and neuro genic cerebrovasodilation, NO may act on vascular smooth muscles directly and contribute to the vas cular relaxation. In other responses, for example, hypercapnia, NO may not contribute directly to the vascular relaxation, but its presence may be re quired for the full expression of the vasodilation. Therefore, NO may serve different roles in cerebro vascular regulation, depending on the vascular re sponse.
As reviewed in the previous sections, NO may participate in the neurogenic vasodilation and in the vasodilation elicited by hypercapnia, hypoglyce mia, and volatile anesthetics. A common feature of these responses is that they are not initiated by an increase in brain metabolism. This observation raises the possibility that NO is involved predomi nantly in luxury perfusion states, that is, vasodilator responses characterized by an "uncoupling" be tween CBF and metabolism. In contrast with this interpretation, however, are the findings that NO may also take part in increases in CBF, such as those elicited by vibrissal stimulation, that are "coupled" to metabolism.
One of the fundamental issues that remains to be resolved is whether the attenuation of vasodilator responses by NOS inhibitors reflects an involve ment of NO in the processes leading to vasodilation or whether it is a nonspecific consequence of the vasoconstriction induced by these agents. If the ef fect of NOS inhibitors were a nonspecific conse quence of vasoconstriction, then all vasodilator re sponses would be reduced equally. Moreover, re sponses that are attenuated by NOS inhibitors would show a comparable attenuation if vascular tone was increased by other mechanisms. Accord ingly, the following arguments support the hypoth esis that the effects of NOS inhibitors do not result solely from an increase in vascular tone: (a) NOS inhibitors do not reduce all vasodilator responses of the cerebral circulation equally, and (b) responses that are attenuated by NOS inhibitors are not influ enced by a comparable increase in vascular tone produced by other mechanisms (Iadecola et aI., 1993a,b) . It must also be emphasized that NOS in hibitors do not impair the reactivity of vascular smooth muscles because these agents do not atten uate the vasodilation elicited by papaverine or ni troprusside, vasodilators that act directly on vascu lar smooth muscles. The main argument supporting the hypothesis that the effects of NOS inhibitors are secondary to the associated vasoconstriction is that, with the possible exception of the vasodilation elicited by topical ACh, ADP, or L-arginine (e.g., Rosenblum et aI., 1990; Mayhan, 1992) , NOS inhib itors attenuate vasodilator responses at concentra tions that also reduce the resting CBF or resting vascular diameter. In this regard, a complicating factor is that relatively high concentrations and a prolonged application time are required to inhibit brain NOS substantially, particularly in vascular re sponses initiated by neural activation (Irikura et aI., 1993 (Irikura et aI., , 1994 . Therefore, direct measurement of NO production in vivo will be important to provide ad ditional evidence on the role of NO synthesis in cerebrovascular regulation. In addition to its action as a vasodilator, NO could also influence microvas cular flow by inhibiting platelet aggregation and leu kocyte activation (for a review see Moncada, 1992) . However, it remains to be established whether these hemorheological effects of NO contribute to the regulation of the cerebral microcirculation in
VlVO.
Regarding the relationship between NO and the endothelium-derived relaxing factor (EDRF), the J Cereb Blood Flow Metab, Vol. 14, No. 2, 1994 observation that the vasodilation elicited by topical ACh is attenuated by inhibitors of NO synthesis suggests that NO, or a NO-containing compound , is the EDRF released from endothelial cells in re sponse to ACh (EDRF ACh) (Faraci, 1990; Rosen blum et aI., 1990; Wei et aI., 1992 ; for a review see Rosenblum, 1992; Faraci, 1993) . Pharmacological data indicate that in the cat cerebral microcircula tion EDRF ACh resembles the NO-containing com pound S-nitroso-L-cysteine more than NO (Mar shall et aI., 1988; Wei and Kontos, 1990) . The EDRFs released by other endothelium-dependent vasodilators, such as bradykinin and calcium iono phore A23 187, may be different from EDRF ACh and their identity remains to be determined (for refer ences see Rosenblum, 1992) .
CEREBRAL ISCHEMIA AND REPERFUSION
In addition to its molecular messenger function, NO is also a toxic substance (for a review see Nathan, 1992) . In neuronal cultures, NO has been reported to participate in NMDA-mediated cytotox icity, an effect that has been attributed to the ability of NO to generate highly toxic free radical species and to inhibit energy metabolism (see Dawson et aI. , 1993) . These observations have suggested that NO may also play a role in cerebral ischemic dam age. Indeed, Kader et al. (1993) , Malinski et al. (1993) , and Sato et al. (1993) have provided evi dence that significant amounts of NO are produced within the rat brain after the onset of cerebral isch emia. Using a porphyrinic microsensor with elec trochemical detection to measure NO directly, Ma linski et al. (1993) noted dramatic increases in NO, from <10 nM to 2.2 j.LM, occurring 3-24 min after transient middle cerebral artery occlusion. NO lev els then decreased slowly over the ensuing hour, with a half-decay time of approximately 30 min. Consistent with these findings, Kader et ai. (1993) detected elevations in nitrite ion, a NO metabolite, cGMP, and NOS activity beginning minutes after the onset of focal ischemia, whereas Sato et al. (1993) reported an increase in NO, detected by elec tron paramagnetic resonance spectroscopy, which was commensurate with the degree of global isch emia. Most likely, the increase in NOS activity is mediated by mobilization of calcium during isch emia. The source of NO (neuronal, glial, and/or vas cular) is yet unclear.
The role of NO in the mechanisms of cerebral ischemia remains unknown. A number of investiga tions have studied the effect of inhibition of NO synthesis on focal cerebral ischemic damage. These studies, summarized in Table 4 , contain apparent TIC staining) L-NAME, 3 mg/kg, i.p., x 3 post-2 days Reduction, 35% treat.
(cortex + striatum) L- NA, 30 mg/kg, s.c. , No change and 30 min posttreat. L-NAME, 5 mg/kg, i.v., 15 min 3 days Increase, > 100% pretreat.
L-NA, 1 mg/kg, i.p., x 3 post-1 day Increase, 67% treat.
2 days Increase, 21% L-NAME, 3 mg/kg, i.p., x 5 postreat. L-NA, 1 mg/kg, i.p., x 3 post-1 day Increase, 68% treat.
2 days No change L-NAME, 3mg/kg, i.p. , x 5 posttreat. L-NA, 1 mg/kg, i.p., x5 3 days Reduction, 50% posttreat. L-NAME, 10 mg/kg, i.v. , 4h Reduction in caudate pretreat.
nucleus, not cortex L-NA 1, mg/kg, i.p., x 5 post-7 days Reduction, 72% treat. L-NA, 100 mg/kg, i.p., 15 h 10 days Reduction, 100% posttreat.
L-NA, 2.4 mg/kgIh x 1 h, i.v. , 24 h Increase, 32% posttreat L-NAME, 10 mg/kgIh x 1 h, i.c., 24 h Increase, 60% posttreat.
MCA, middle cerebral artery ; SD, Sprague-Dawley ; SHR, spontaneously hypertensive rats; TTC , 2, 3 , a.v., artificial ventilation; i.c. , intracarotidally; i.p., intraperitoneally; i.v., intravenously; s.v. , spontaneous ventilation; treat. , treatment. contradictions that defy explanation. No simple patterns emerge. Some studies show that inhibition of NO synthesis produces a marked reduction of infarct size, whereas other studies found that NOS inhibition increases infarct size. Reduction or wors ening of ischemic damage has been reported under different conditions of anesthesia or with no anes thesia at all. In most studies, the middle cerebral artery was permanently occluded, whereas revers ible focal ischemia has received less attention. Nor motensive rats were used in some studies, and SHR in others. Some protocols used L-NAME, whereas others L-NA. In some reports, NOS inhibitors were administered prior to MCA occlusion, as posttreat ment, or both. Among the studies showing tissue protection after NOS inhibition, outcome was as sessed as early as 4 h and as late as 10 days, whereas enhanced injury was reported at 4-72 h after the onset of focal ischemia. When tissue pro tection was observed, the magnitude of injury re duction ranged from 100 to 35%, whereas when in creases in infarct size were observed injury size was greater by 30-70%. Decreased infarct size was noted in mice, cats (caudate nucleus only), and rats (adults and neonates), whereas increased tissue in jury was reported in rats only.
Some studies have indicated that the vascular ef fects of NO are an important determinant of tissue outcome during focal ischemia. Administration of L-arginine, but not D-arginine, increases CBF within the ischemic penumbra and reduces infarct size (Morikawa et al., 1992a,b; Hamberg et al., 1993) . The most likely site for the conversion of L-arginine into NO is in cerebral blood vessels be cause (a) L-arginine-induced pial dilatation can be blocked by topical L-NAME at concentrations and time intervals that do not reduce brain NOS activity (Morikawa et al., 1992b) and (b) the L-arginine induced CBF increase develops minutes before re covery of the electroencephalographic (EEG) am plitude in the ischemic penumbra, suggesting that the blood flow response reflects events other than those related to neuronal activity (Dalkara et al., 1993) . Although the participation of glial cells and/ or perivascular nerves cannot be completely ruled out at this time, increased precursor levels com bined with increased NOS activity in vessels prob ably account for the ameliorative effects of L-argi nine in these models. In addition, administration of the NO donor sodium nitroprusside or 3-mor pholino sydnonimine (SIN 1) increases CBF in the ischemic area, improves EEG recovery, and re duces focal ischemic damage Zhang et al., 1994) . A reduction in focal isch emic damage was also observed after pretreatment with isosorbide trinitrate (Buisson et al., 1993) . Be-cause the protective effect exerted by NO donors occurs in the absence of inhibition of platelet aggre gation (Zhang et aI., 1994) , the main mechanism of the protection may be related to NO-mediated va sodilation. Collectively, these observations indicate that, through its vascular effects, NO leads to an increase in collateral blood flow to the ischemic ter ritory, resulting in a reduction in focal cerebral isch emic damage.
Much less is known about the role of NO in global ischemia and the consequences of inhibiting its syn thesis on blood flow and measures of tissue out come. In one report L-NAME inhibited blood flow normalization during the reperfusion period after 10 min of bilateral common carotid artery occlusion (Prado et aI., 1993) . In a second preliminary report, L-NAME caused a reduction and delay in the hy peremic response during the reperfusion period fol lowing combined common carotid artery occlusion and hypotension, an effect that was prevented by coadministration of L-arginine (Maynard et aI., 1993) . The effects of NOS inhibition on tissue out come were reported by two laboratories. One study reported that L-NAME did not affect the extent of tissue damage when administered prior to ischemia in the rat (Moncada et aI., 1992) , whereas another study noted increased cell damage when L-NA was given prior to bilateral carotid occlusion (5 min) and reperfusion (6 days) in the gerbil (Weissman et aI., 1992) .
Therefore, the precise role that NO plays within the ischemic tissue remains a complex issue. Com pelling arguments have been advanced for both NO mediated cytotoxic effects and NO-mediated tissue sparing effects based on antiplatelet and vasodilat ing actions. Both effects are likely to be important. The prevailing mechanism may well depend in part upon the amount of NO generated, the tissue com partment generating NO, the time following the on set of ischemia, and the integrity of guanylate cy clase and its dependent reactions. In addition, re cent data suggest that the redox state of the tissue may have an important impact on whether nitro so compounds, including NO, are neurotoxic or neu roprotective. Alternative redox forms of nitrogen monoxide are NO (NO ') and nitrosonium (NO +) (Stamler et aI. , 1992) . Studies in neuronal cultures suggest that NO donors are neurotoxic if the redox state of the medium favors formation of NO ' and are neuroprotective if the redox milieu favors NO + formation (Lipton et aI., 1993) . The destructive ef fect of NO ' appears to be mediated by peroxynitrite formation whereas the neuroprotective effect may be linked to S-nitrosylation of NMDA receptor thiol groups, a process resulting in downregulation of the J Cereb Blood Flow Metab, Vol. 14, No. 2, 1994 NMDA receptor and attenuation of NMDA mediated neurotoxicity (Lipton et aI., 1993) . It re mains to be established, however, whether the re dox state of the ischemic tissue can determine the neuroprotective or neurotoxic character of nitro so compounds produced endogenously.
It is therefore not surprising that tissue outcome studies in focal cerebral ischemia produce conflict ing results. Differences in either methodology or the models themselves may also contribute to the con troversy. For example, injury in the hypoxic ischemic neonatal rat may be more dependent on excitotoxic mechanisms and less on reductions in blood flow than models in which tissue injury is initialed by vascular occlusion only. Furthermore, in transient focal ischemia models increased free radical activity may play a more important role in the pathophysiology of tissue damage. Finally, dif ferences in the timing of administration of NOS in hibitors relative to the induction of the ischemia and differences in the route and dose of administration of the inhibitors are also likely to contribute to the variability of these studies.
CONCLUSIONS
Studies using NOS inhibitors have provided ini tial evidence that NO is involved in the regulation of CBF. While there is agreement on the participation of NO in the maintenance of resting CBF, there are still disagreements on the role of NO in other vas cular responses of the cerebral circulation. Some of the conflicting results may derive from the fact that doses and routes of administration of NOS inhibi tors have varied widely among studies. It is becom ing increasingly clear that the attenuation of physi ological responses is related to the degree of NOS inhibition and that the degree of NOS inhibition de pends on (a) the arginine analogue used, (b) the dose and route of administration, and (c) the time interval between administration of the drug and testing of the response. Therefore, measurement of NOS activity ex vivo will be important in investi gations using NOS inhibitors in vivo. Furthermore, the hypotheses formulated on the basis of experi ments using NOS inhibitors need to be tested by direct measurements of NO production using detec tion techniques applicable in vivo (Archer, 1993) . In addition, the role of NO in cerebrovascular regula tion, which so far has been studied mostly in rat, needs to be explored in other species.
There is still substantial controversy regarding the role of NO in ischemic damage. Although there is evidence that the vascular actions of NO may be beneficial in the early stages of focal ischemia, the role that "parenchymal" NO production plays in the pathophysiology of the tissue damage remains to be defined. Evidence has been presented favor ing both a beneficial and a detrimental effect of NO in focal ischemia. Although some of the conflicting findings could result from differences in species, strain, and age of animals, ischemic models, and protocols for administration of the drug, NO may have a "double-edged" role in cerebral ischemia, as has been proposed in other organ systems (e.g., Beckman, 199 1; Schmidt et aI., 1992) . The subject clearly warrants further investigation.
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